The abstract is read at the publisher; the summary is JClub's.
Inebilizumab reduced exacerbation risk in randomized phase 3 myasthenia gravis (gMG) patients, with hazard ratios of 0.41 by week 26 overall.
- Why it matters: Uncontrolled gMG exacerbations often require rescue therapy, particularly in moderate-to-severe disease, and prior trial results needed clearer quantification of this benefit.
- What they did: In MINT (485 screened; 238 enrolled), adults with MG-ADL 6–10 were randomized 1:1 to inebilizumab or placebo with a protocol corticosteroid taper to ≤5 mg/day. Exacerbations included myasthenic crisis, MG-ADL worsening, or rescue therapy (IVIG or plasma exchange).
- The result: By week 26, exacerbation risk was lower with inebilizumab versus placebo (HR 0.41; 95% CI, 0.24–0.70), including AChR+ (HR 0.39 by week 52) and MuSK+ (HR 0.21 by week 26), supporting reduced exacerbations and rescue therapy use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.